导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.42% | 2811/4773 |
| 近一周 | -1.51% | 2248/5465 |
| 近一月 | -3.17% | 2235/5421 |
| 近一季 | -7.21% | 2716/5231 |
| 近半年 | -3.21% | 2426/4920 |
| 近一年 | 0.54% | 2674/4394 |
| 近两年 | 46.33% | 1620/2954 |
| 近三年 | 26.57% | 1239/2253 |
| 成立以来 | 42.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.52% 3261/4961 |
12.77% 2120/5312 |
- - |
- - |
| 2025 | 19.85% 2177/4813 |
-1.05% 2559/3635 |
1.78% 2143/4076 |
19.01% 2205/4524 |
-0.01% 2297/4813 |
| 2024 | 14.72% 1017/3463 |
2.29% 800/2808 |
-1.60% 1081/3014 |
16.64% 1395/3129 |
-2.29% 2030/3463 |
| 2023 | -11.03% 1364/2656 |
3.55% 1170/2280 |
-5.14% 1386/2385 |
-3.39% 915/2515 |
-6.24% 1687/2655 |
| 2022 | -19.25% 824/2207 |
-14.46% 948/1919 |
7.14% 523/2016 |
-12.89% 802/2113 |
1.14% 1371/2208 |
| 2021 | 5.70% 538/1822 |
-2.52% 661/1255 |
9.12% 583/1330 |
-2.72% 590/1466 |
2.15% 679/1822 |
| 2020 | - - |
- - |
- - |
10.46% 551/1164 |
13.71% 337/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 摩根MSCI中国A股ETF VS. 长安沪深300非周期A(740101) |